Robert J Straka

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6960955/publications.pdf

Version: 2024-02-01

79	2,430	196777 29	263392 45
papers	citations	h-index	g-index

79	79	79	3760
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	<scp>PharmVar GeneFocus</scp>: <scp>SLCO1B1</scp>. Clinical Pharmacology and Therapeutics, 2023, 113, 782-793.	2.3	18
2	The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statinâ€Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics, 2022, 111, 1007-1021.	2.3	120
3	The Identification of Novel CYP2D6 Variants in US Hmong: Results From Genome Sequencing and Clinical Genotyping. Frontiers in Pharmacology, 2022, 13, 867331.	1.6	4
4	Differences in Predicted Warfarin Dosing Requirements Between Hmong and East Asians Using Genotypeâ€Based Dosing Algorithms. Pharmacotherapy, 2021, 41, 265-276.	1.2	8
5	Gout prevalence in the Hmong: aÂprime example of health disparity and the role of community-based genetic research. Personalized Medicine, 2021, 18, 311-327.	0.8	12
6	Pharmacogenomics education, researchÂand clinical implementation in the state of Minnesota. Pharmacogenomics, 2021, 22, 681-691.	0.6	11
7	Potential Clinical Relevance of Differences in Allele Frequencies Found within Very Important Pharmacogenes between Hmong and East Asian Populations. Pharmacotherapy, 2020, 40, 142-152.	1.2	8
8	HLA-B*58:01 carrier status of Hmong in Minnesota: first in Hmong genotyping for prevalence of this biomarker of risk for severe cutaneous adverse reactions caused by allopurinol. Pharmacogenetics and Genomics, 2020, 30, 21-25.	0.7	3
9	Randomised clinical study: oral aspirin 325Âmg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk. Alimentary Pharmacology and Therapeutics, 2020, 52, 976-987.	1.9	40
10	Salivary AMY1 Copy Number Variation Modifies Age-Related Type 2 Diabetes Risk. Clinical Chemistry, 2020, 66, 718-726.	1.5	7
11	Precision medicine in adult and pediatric obesity: a clinical perspective. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881986302.	1.4	30
12	An Exome-Wide Sequencing Study of the GOLDN Cohort Reveals Novel Associations of Coding Variants and Fasting Plasma Lipids. Frontiers in Genetics, 2019, 10, 158.	1.1	2
13	An exome-wide sequencing study of lipid response to high-fat meal and fenofibrate in Caucasians from the GOLDN cohort. Journal of Lipid Research, 2018, 59, 722-729.	2.0	10
14	Potential Clinical and Economic Impact of Switching Branded Medications to Generics. American Journal of Therapeutics, 2017, 24, e278-e289.	0.5	50
15	Engaging Hmong adults in genomicÂandÂpharmacogenomic research: Toward reducing health disparities in genomic knowledge using a community-based participatory research approach. Journal of Community Genetics, 2017, 8, 117-125.	0.5	23
16	Sex Differences in Blood HDLâ€¢, the Total Cholesterol/HDLâ€¢ Ratio, and Palmitoleic Acid are Not Associated with Variants in Common Candidate Genes. Lipids, 2017, 52, 969-980.	0.7	19
17	Leaves imitate trees: Minnesota Hmong concepts of heredity and applications to genomics research. Journal of Community Genetics, 2017, 8, 23-34.	0.5	11
18	A genome-wide study of lipid response to fenofibrate in Caucasians. Pharmacogenetics and Genomics, 2016, 26, 324-333.	0.7	12

#	Article	IF	Citations
19	Assessment of postprandial triglycerides in clinical practice: Validation in a general population and coronary heart disease patients. Journal of Clinical Lipidology, 2016, 10, 1163-1171.	0.6	22
20	Assessment of genetic polymorphisms associated with hyperuricemia or gout in the Hmong. Personalized Medicine, 2016, 13, 429-440.	0.8	24
21	A family-specific linkage analysis of blood lipid response to fenofibrate in the Genetics of Lipid Lowering Drug and Diet Network. Pharmacogenetics and Genomics, 2015, 25, 511-514.	0.7	3
22	Gene-Environment Interactions of Circadian-Related Genes for Cardiometabolic Traits. Diabetes Care, 2015, 38, 1456-1466.	4.3	52
23	Genetic Risk Scores Associated with Baseline Lipoprotein Subfraction Concentrations Do Not Associate with Their Responses to Fenofibrate. Biology, 2014, 3, 536-550.	1.3	1
24	Ethnic and genetic factors in methadone pharmacokinetics: A population pharmacokinetic study. Drug and Alcohol Dependence, 2014, 145, 185-193.	1.6	40
25	Student-generated, faculty-vetted multiple-choice questions: Value, participant satisfaction, and workload. Currents in Pharmacy Teaching and Learning, 2014, 6, 15-21.	0.4	6
26	Genome-wide association studies identified novel loci for non-high-density lipoprotein cholesterol and its postprandial lipemic response. Human Genetics, 2014, 133, 919-930.	1.8	10
27	Genetic Analysis of 16 NMRâ€Lipoprotein Fractions in Humans, the GOLDN Study. Lipids, 2013, 48, 155-165.	0.7	34
28	Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies. Expert Review of Cardiovascular Therapy, 2013, 11, 355-364.	0.6	8
29	Genetic variants associated with VLDL, LDL and HDL particle size differ with race/ethnicity. Human Genetics, 2013, 132, 405-413.	1.8	30
30	The Effect of CYP7A1 Polymorphisms on Lipid Responses to Fenofibrate. Journal of Cardiovascular Pharmacology, 2012, 59, 254-259.	0.8	23
31	A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network. Pharmacogenetics and Genomics, 2012, 22, 191-197.	0.7	55
32	Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate. Pharmacogenetics and Genomics, 2012, 22, 750-757.	0.7	15
33	Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: A pilot study. Digestive and Liver Disease, 2012, 44, 303-310.	0.4	118
34	Variants Identified in a GWAS Meta-Analysis for Blood Lipids Are Associated with the Lipid Response to Fenofibrate. PLoS ONE, 2012, 7, e48663.	1.1	39
35	Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study. Pharmacogenetics and Genomics, 2012, 22, 367-372.	0.7	11
36	Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status. Atherosclerosis, 2011, 215, 435-439.	0.4	19

#	Article	IF	Citations
37	Profiling Circulating and Urinary Bile Acids in Patients with Biliary Obstruction before and after Biliary Stenting. PLoS ONE, 2011, 6, e22094.	1.1	87
38	Determining initial and follow-up costs of cardiovascular events in a US managed care population. BMC Cardiovascular Disorders, 2011, 11, 11.	0.7	25
39	High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering drugs and diet network (GOLDN): an interventional study. Lipids in Health and Disease, 2011, 10, 181.	1.2	74
40	Apolipoprotein E Polymorphisms and Postprandial Triglyceridemia Before and After Fenofibrate Treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study. Circulation: Cardiovascular Genetics, 2010, 3, 462-467.	5.1	39
41	Fenofibrate and Metabolic Syndrome. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2010, 10, 138-148.	0.6	34
42	Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. Molecular Genetics and Metabolism, 2010, 100, 118-122.	0.5	22
43	Comparison of Postprandial Responses to a High-Fat Meal in Hypertriglyceridemic Men and Women before and after Treatment with Fenofibrate in the Genetics and Lipid Lowering Drugs and Diet Network (GOLDN) Study. SRX Pharmacology, 2010, 2010, 1-8.	0.2	3
44	In Vitro Glucuronidation of Fenofibric Acid by Human UDP-Glucuronosyltransferases and Liver Microsomes. Drug Metabolism and Disposition, 2009, 37, 2236-2243.	1.7	17
45	Genetic Variants at the PDZ-Interacting Domain of the Scavenger Receptor Class B Type I Interact with Diet to Influence the Risk of Metabolic Syndrome in Obese Men and Women. Journal of Nutrition, 2009, 139, 842-848.	1.3	19
46	Novel variants at KCTD10, MVK, and MMAB genes interact with dietary carbohydrates to modulate HDL-cholesterol concentrations in the Genetics of Lipid Lowering Drugs and Diet Network Study. American Journal of Clinical Nutrition, 2009, 90, 686-694.	2.2	25
47	Polyunsaturated Fatty Acids Modulate the Effect of TCF7L2 Gene Variants on Postprandial Lipemia. Journal of Nutrition, 2009, 139, 439-446.	1.3	45
48	Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states. American Journal of Clinical Nutrition, 2009, 89, 391-399.	2.2	52
49	Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovascular Diabetology, 2009, 8, 53.	2.7	43
50	WDTC1, the Ortholog of Drosophila Adipose Gene, Associates With Human Obesity, Modulated by MUFA Intake. Obesity, 2009, 17, 593-600.	1.5	38
51	ADIPOQ Polymorphisms, Monounsaturated Fatty Acids, and Obesity Risk: The GOLDN Study. Obesity, 2009, 17, 510-517.	1.5	80
52	Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the Genetics of Lipid-Lowering Drugs and Diet Network study. Pharmacogenetics and Genomics, 2009, 19, 161-169.	0.7	45
53	The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions. Journal of Human Genetics, 2008, 53, 709-717.	1.1	32
54	The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. European Journal of Human Genetics, 2008, 16, 603-613.	1.4	35

#	Article	IF	Citations
55	Association of Common C-Reactive Protein (CRP) Gene Polymorphisms With Baseline Plasma CRP Levels and Fenofibrate Response. Diabetes Care, 2008, 31, 910-915.	4.3	44
56	The effect of IL6-174C/G polymorphism on postprandial triglyceride metabolism in the GOLDN study*. Journal of Lipid Research, 2008, 49, 1839-1845.	2.0	22
57	Economic impacts attributable to the early clinical benefit of atorvastatin therapy â€“ a US managed care perspective. Current Medical Research and Opinion, 2007, 23, 1517-1529.	0.9	13
58	The â^'256T>C Polymorphism in the Apolipoprotein A-II Gene Promoter Is Associated with Body Mass Index and Food Intake in the Genetics of Lipid Lowering Drugs and Diet Network Study. Clinical Chemistry, 2007, 53, 1144-1152.	1.5	113
59	Fenofibrate Effect on Triglyceride and Postprandial Response of Apolipoprotein A5 Variants. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1417-1425.	1.1	113
60	Determination of Fenofibric Acid Concentrations by HPLC After Anion Exchange Solid-Phase Extraction From Human Serum. Therapeutic Drug Monitoring, 2007, 29, 197-202.	1.0	16
61	Interleukin1Î² Genetic Polymorphisms Interact with Polyunsaturated Fatty Acids to Modulate Risk of the Metabolic Syndrome , ,3. Journal of Nutrition, 2007, 137, 1846-1851.	1.3	59
62	Mixture Models and Subpopulation Classification: A Pharmacokinetic Simulation Study and Application to Metoprolol CYP2D6 Phenotype. Journal of Pharmacokinetics and Pharmacodynamics, 2007, 34, 141-156.	0.8	18
63	Discordance Between N-acetyltransferase 2 Phenotype and Genotype in a Population of Hmong Subjects. Journal of Clinical Pharmacology, 2006, 46, 802-811.	1.0	11
64	Verified predominance of slow acetylator phenotype N-acetyltransferase 2 (NAT2) in a Hmong population residing in Minnesota. Biopharmaceutics and Drug Disposition, 2006, 27, 299-304.	1.1	1
65	Effect of influenza vaccine on markers of inflammation and lipid profile. Translational Research, 2005, 145, 323-327.	2.4	89
66	Achieving Cholesterol Target in a Managed Care Organization (ACTION) Trial. Pharmacotherapy, 2005, 25, 360-371.	1.2	30
67	Assessment of Hypercholesterolemia Control in a Managed Care Organization. Pharmacotherapy, 2001, 21, 818-827.	1.2	45
68	Evaluation of the Influence of Diabetes Mellitus on Antipyrine Metabolism and CYP1A2 and CYP2D6 Activity. Pharmacotherapy, 2000, 20, 182-190.	1.2	58
69	Magnitude and Nature of Noncompliance with Treatment using Isosorbide Dinitrate in Patients with Ischemic Heart Disease. Journal of Clinical Pharmacology, 1996, 36, 587-594.	1.0	17
70	Chronopharmacologic Considerations When Treating the Patient with Hypertension: A Review. Journal of Clinical Pharmacology, 1996, 36, 771-782.	1.0	16
71	Predominance of Slow Acetylators of Nâ€acetyltransferase in a Hmong Population Residing in the United States. Journal of Clinical Pharmacology, 1996, 36, 740-747.	1.0	7
72	Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota*. Clinical Pharmacology and Therapeutics, 1995, 58, 29-34.	2.3	25

#	Article	IF	Citations
73	The Clinical Significance of the Pharmacogenetics of Cardiovascular Medications. Journal of Pharmacy Practice, 1992, 5, 337-361.	0.5	2
74	Determination of Dextromethorphan and Its O-Demethylated Metabolite from Urine. Therapeutic Drug Monitoring, 1992, 14, 402-407.	1.0	22
75	Improved Selectivity of a High-Performance Liquid Chromatography Assay for Debrisoquine and Its 4-Hydroxy Metabolite from Urine. Therapeutic Drug Monitoring, 1990, 12, 478-480.	1.0	7
76	Analysis of metoprolol enantiomers in human serum by liquid chromatography on a cellulose-based chiral stationary phase. Biomedical Applications, 1990, 530, 83-93.	1.7	25
77	Measurement of underivatized propranolol enantiomers in serum using a cellulose-tris(3,5-dimethylphenylcarbamate) high-performance liquid chromatographic (HPLC) chiral stationary phase. Pharmaceutical Research, 1988, 05, 187-189.	1.7	28
78	Nonlinear Pharmacokinetics of Unbound Propranolol after Oral Administration. Journal of Pharmaceutical Sciences, 1987, 76, 521-524.	1.6	19
79	Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers. Journal of Pharmacokinetics and Pharmacodynamics, 1987, 15, 569-582.	0.6	17